Eisai India wins CII Excellence Award for EHS

L to R: K Srinivas Rao, Deputy Manager, EISAI; Anand Galphade, Deputy General Manager, EISAI; Sunil Kumar, Vice President – Operations, EISAI receiving the award from CII

Eisai Pharmatechnology & Manufacturing, Visakhapatnam (Eisai) has been awarded the prestigious Environment, Health, and Safety (EHS) Excellence 2012 Award by the Confederation of Indian Industry (CII) Southern Region. Eisai is a 100 per cent subsidiary of Eisai Japan, which ranks among the top 25 pharmaceutical companies in the world by revenue.

The Eisai facility at Visakhapatnam was ranked best under the pharma-food-refinery sector. It also bagged the top honour amongst the Medium Scale Industries. More than 100 companies participated in the award competition. CII auditors made an on-site assessment of all the participating companies and evaluated their EHS systems and practices on about 150 parameters. The aim of this award is to recognise, motivate, facilitate and acknowledge extraordinary contribution by organisations to adopt excellent practices in environment, health and safety.

On receiving the award, Sanjit Singh Lamba, Managing Director of the company said, “Achieving the CII recognition within three years of commencement of operations validates the company’s sound EHS systems, work culture, and practices. It inspires us to strive harder for sustained excellence”. Eisai’s corporate human health care (hhc) mission is to give first thought to patients and their families, and to increase the benefits that healthcare provides. The company believes that increasing patient satisfaction through the development of innovative new medicines exemplifies its important mission, he added.

In line with its human health care (hhc) mission, EISAI is committed to improving global access to medicines over medium to long-term through partnership strategies that involve working with governments, international organisations, private entities and non-profit organisations.

The Visakhapatnam plant is central to EISAI’s efforts to supply its off-patent medicines at affordable prices to patients in India as well as across the developing world. Production at Visakhapatnam, which is cost-competitive and high quality, helps EISAI expand access to medicines in developing countries. The company is also committed to supply 2.2 billion tablets of DEC (Diethylcarbamazine) free of charge to the World Health Organization (WHO). The medicine, essential for elimination of the neglected tropical disease lymphatic filariasis, will be manufactured at Visakhapatnam for free supply to 250 million people in developing countries around the world through WHO.

EP News Bureau – Mumbai